Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.1B 949M 886M 813M 1.53B 104B 1.55B 10.4B 4.08B 52.34B 4.12B 4.03B 173B P/E 2026 *
-15x
P/E 2027 * -13x
Enterprise Value 1.1B 949M 886M 813M 1.53B 104B 1.55B 10.4B 4.08B 52.34B 4.12B 4.03B 173B EV / Sales 2026 *
31.6x
EV / Sales 2027 * 37.3x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day+4.66%
1 week+6.93%
Current month+6.93%
1 month+4.22%
3 months+47.02%
6 months+100.81%
Current year+114.78%
1 week 1.96
Extreme 1.96
2.52
1 month 1.96
Extreme 1.96
2.52
Current year 1.1
Extreme 1.1
2.68
1 year 1.02
Extreme 1.02
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
28/02/26 Fiscal year

General Counsel

651,031 0.1792%
28/02/26 Fiscal year

Chief Executive Officer

1,211,357 0.3333%
28/02/26 Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
+4.66%+6.93%+120.54%+45.29% 1.1B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.93%+11.21%+59.67%+190.82% 26.47B
Weighted average by Cap. +4.36%+13.07%+49.78%+167.98%

Financials

2026 *2027 *
Net sales 34.72M 30.03M 28.05M 25.73M 48.39M 3.3B 49.16M 329M 129M 1.66B 130M 128M 5.48B 29.4M 25.43M 23.75M 21.79M 40.98M 2.8B 41.63M 279M 109M 1.4B 110M 108M 4.64B
Net income -78.3M -67.73M -63.25M -58.02M -109M -7.45B -111M -742M -291M -3.74B -294M -288M -12.35B -88.54M -76.58M -71.52M -65.61M -123M -8.43B -125M -839M -329M -4.22B -332M -325M -13.96B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
07/08/26 $2.470 +4.66% 3,085,740
06/08/26 $2.360 -3.67% 4,890,832
05/08/26 $2.450 -1.61% 3,974,293
04/08/26 $2.490 +6.87% 3,908,893
03/08/26 $2.330 +0.87% 2,053,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.470USD
Average target price
3.856USD
Spread / Average Target
+56.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock